Douglas Flora, MD, LSSBB, FACCC’s Post

Our true north at Ryght is to help those who strive everyday to help cure cancer, treat patients and make a difference. Chadi Nabhan, MD, MBA,FACP, our esteemed Chief Medical Officer, has written another insightful book which should be the manual for anyone dealing with this dreaded disease. Buy it at the link below.

NHS partners with data specialist Arcturis for cancer research The health data specialist has entered into a multi-year strategic research agreement with Guy's and St Thomas' NHS Foundation Trust St Thomas’ NHS Foundation Trust to advance cancer research To read more, follow the link to the Building Better Healthcare article #NHS #UKhealthcare #cancerresearch #dataspecialist

Thinking about it- this must be my ultimate bugbear topic. I've always been a hopeless optimiser, I somehow just don't seem to be able to *resist* how one could improve this or that. And since my husband was diagnosed with #Melanoma in 2011 and needed clinical trials- how to make research better and more relevant and how to turn research results into patient outcomes as fast as possible have been the undercurrent to most of my work. And considering that many EU projects and initiatives still misuse patient organisations as their communication department (you can talk about it but got zero influence on what it is) and define successful patient engagement as 'patient agrees with me' (no joke, just seen today)- the source of plenty of personal frustration. So it's cool to be able to talk about things that went actually well in that respect, one in PCM4EU - Personalised Cancer Medicine for all EU citizens and one in PRIME-ROSE and that taught me plenty on what it takes to make interactions between patient communities and traditional research consortia not only meaningful but actually, rewarding and downright fun for every party involved. The spoiler? Patient organisations need to stop allowing to be co-opted- and get sharper on the results they want to see for their communities #Return_on_engagement And for the rest ;), well see you at #ESMO24 next Sunday!

COTA and Texas Oncology’s Precision Health Informatics, LLC collaborate to use #AI in transforming healthcare data into actionable insights, enhancing #precisionmedicine and #cancer care. Read at The Evidence Base® #rwe #rwd #realworldevidence #realworlddata #healthdata #electronichealthrecords #EHRs #oncology #artificialintelligence

"Without decision support, it takes five years or more for a clinical practice guideline to be integrated into care, but through technology and particularly clinical decision support, we can expedite the delivery of this information to the point of care and thus use the best practices for symptom management." -David Lobach   David Lobach, MD, PhD, participated in a panel session titled "Treating the Individual" at the 2023 Clinical Pathways Congress + Cancer Care Business Exchange.   In this interview, Dr Lobach provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.   Check out the full interview here: https://lnkd.in/e-pnxYrd   #JournalOfClinicalPathways #CancerCare #ValueBasedCare #ClinicalDecisionSupport

Uncover the essential steps to quality improvement in cancer care with our latest coverage from Association of Cancer Care Centers’ 50th Annual Meeting & Cancer Center Business Summit. Explore actionable insights and strategies to enhance patient outcomes and streamline health care delivery here: #AMCCBS24

Dr. Keegan Duchicela, M.D. has firsthand experience evaluating for cancer risk in patients during 15-minute PCP visits. The short of it? Assessing for cancer risk in a routine PCP setting is challenging, complex, and...fast. Alongside Wendy McKennon, Chief Product Innovation Officer at Color, Keegan has written about how AI tools can help synthesize critical information for clinicians. Here's how our new copilot, created with OpenAI, is designed to help PCPs navigate cancer screening recommendations, detection, and care—all while adhering to a "human in the loop" model. ⤵ https://lnkd.in/gDabKQq4

Our AI journey continues as we announced CareIntellect for Oncology, an AI-powered tool that helps clinicians gain a comprehensive view of a patient’s cancer journey in one place. The platform goes beyond data aggregation, offering an organized look at disease progression and supporting proactive care interventions. It simplifies access to patient histories, clinical trial eligibility, and treatment adherence. Tampa General Hospital and UT Southwestern Medical Center will be early evaluators. This is the first application of our GE HealthCare CareIntellect suite, designed to streamline healthcare technology adoption and improve clinical efficiency. Here is what our leaders and partners say: “CareIntellect is designed to help providers streamline access to critical patient information and surface key changes since the patient’s last visit. By ensuring the provider has the right information at their fingertips, they can spend less time sifting through information and more time helping patients.” Taha Kass-Hout, MD, MS, Global Chief Science and Technology Officer at GE HealthCare “Tampa General Hospital is looking forward to evaluating CareIntellect for Oncology to provide our care teams with information to move from analysis to action—including making use of the proactive pathways to inform care progression and clinical trial eligibility information. We were impressed by how quickly GE HealthCare was able to design the application to include breast cancer in a matter of weeks. We look forward to putting this in the hands of our care teams and using the AI-enabled functionality to help clinicians spend time where it matters most—delivering outstanding patient care.” Dr. Peter Chang Senior Vice President, Chief Transformation Officer at Tampa General Hospital. Read the full news release here and visit us at HLTH Inc. to learn more: https://lnkd.in/e8N4ctuZ #AI #GeHealthCare #oncology

🌟 ✨ Thought Leadership in Lung Cancer MDT Decision Making ✨🌟 In healthcare, every decision holds the power to impact. When it comes to lung cancer, Multidisciplinary Team (MDT) meetings serve as the cornerstone for treatment strategies. As we navigate the nuances of patient care, how can we ensure that our decisions are not just informed but also transformative? 🔬 Elevating MDT Dialogues: Collaboration lies at the heart of effective decision-making in lung cancer MDTs. By fostering open dialogues that integrate diverse perspectives, we can uncover innovative solutions that transcend conventional boundaries. 🧠 Harnessing Data Insights: Data has the potential to revolutionize the way we approach lung cancer care. By leveraging advanced analytics and predictive modeling, we can personalize treatment plans and optimize outcomes for each patient. ⚖️ Balancing Science and Compassion: In the pursuit of evidence-based practice, let us not overlook the human aspect of healthcare. Empathy, understanding, and patient-centric care should form the ethical compass guiding our decisions in MDT settings. 💡 Embracing Continuous Learning: To make impactful decisions, we must stay at the forefront of medical advancements, regularly updating our knowledge and refining our approaches. 🚀 Driving Innovation Through Collaboration: By uniting expertise, we can drive innovation in lung cancer care. Let us break traditional silos and embrace a culture of interdisciplinary teamwork to revolutionize MDT decision-making. 🌿 Nurturing Ethical Practice: Upholding integrity, transparency, and respect for patient autonomy should guide our decisions, ensuring that ethics remain at the core of our MDT processes. ITogether, we can make a difference that resonates far beyond the confines of our MDT meetings. #MDT #LungCancer #HealthcareDecisions #ThoughtLeadership 🌟🔬🌿

Dive into the Future of Liquid Biopsy: Join Expert Panel at PMWC 2024 NEXT WEEK Get ready for a groundbreaking discussion on the "Status Quo of Clinical Liquid Biopsy"! This esteemed panel, chaired by Helmy Eltoukhy of Guardant Health, features leading experts from across the globe: Sadakatsu Ikeda (Tokyo Medical University) Heather Parsons (Dana-Farber Cancer Institute) Sanjay Popat (The Royal Marsden NHS Foundation Trust) David Gandara, MD (UC Davis Health) They'll dive deep into the current landscape of liquid biopsy, tackling questions like: -Evolution of Liquid Biopsy: When did they first encounter it in practice? How has its use transformed treatment decisions today? -Global Guidelines: From Japan to the UK and beyond, how do guidelines shape liquid biopsy implementation across different countries? Where do they see the future heading? -Impact on Advanced Cancers: How has liquid biopsy revolutionized treatment for these challenging cases? -Challenges and Opportunities: What hurdles remain? What areas hold the most promise for future advancements? -Beyond Genomics: Dr. Eltoukhy explores the exciting potential of epigenomics in expanding liquid biopsy applications. What other emerging trends are capturing your interest? -Validation and Adoption: What level of evidence is needed for clinicians and developers to feel confident in embracing new liquid biopsy tests? -The Future is Now: Paint a picture of what liquid biopsy integration into cancer care might look like a decade from now. This is a must-attend session for clinicians, researchers, and industry professionals at the forefront of liquid biopsy! Join the conversation, ask your questions, and share your insights about this rapidly evolving field. https://lnkd.in/gW5bwBFP #LiquidBiopsy #PrecisionMedicine #CancerCare #FutureOfOncology, #epigenomics PMWC - Precision Medicine World Conference Matt Burns, Mostafa Ronaghi